Discovery to Commercialization Program for Substance Abuse Prevention and Treatment (D2C: SAPT)
药物滥用预防和治疗发现到商业化计划(D2C:SAPT)
基本信息
- 批准号:10524311
- 负责人:
- 金额:$ 34.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-15 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:Active LearningAddressAdvocateAttentionAwardBasic ScienceBusinessesCaringCertificationClinicClinicalClinical SciencesClinical TreatmentCommunitiesComplementCustomDiagnosisDisabled PersonsEducationEducational CurriculumEducational process of instructingEducational workshopEnrollmentEnsureEntrepreneurshipEvaluationExposure toFeedbackFosteringFoundationsFundingFutureGenerationsGoalsGrantHealthIndividualInstructionIntellectual PropertyKnowledgeLearningLegal patentLicensingMeasuresMentorsModelingParticipantPathway interactionsPatient RecruitmentsPatientsPersonsPlayPositioning AttributePreventionProblem SolvingProcessProfessional EducationProviderPublic HealthRecruitment ActivityResearchResearch PersonnelResource SharingResourcesRoleSchoolsScienceScientistSubstance Use DisorderTimeTrainingTraining ProgramsTranslationsUnderrepresented PopulationsUniversitiesWorkcareercertificate programclinical practicecommercializationcommunity buildingdesigneducation resourcesempoweredevidence baseexperienceideationimprovedinnovationinstructorinterestmeetingsnext generationonline communityprogramsprototyperecruitrole modelsatisfactionscaffoldservice providersskills trainingstemsubstance abuse preventionsubstance abuse treatmentsubstance use treatmentsynchronous contacttoolvirtual
项目摘要
Project Summary
There has been critical underinvestment in Substance Use Disorders (SUDs) and continuing to rely on
the same approaches is not working. In this proposal, we actively seek to support disruptive innovations to
stem the rising tide of SUDs and stimulate progress. Such disruptions are most likely to come from those
actively engaged in treating and advancing knowledge of SUDs. But many in a position to do so are not aware
of or see value in discovery commercialization. Our overarching goals are to have more basic scientists think
like entrepreneurs and to have access to the resources they need to engage in the commercialization
processes. Through our proposed tasks, we will develop and deliver entrepreneurship education that is curated
for basic science researchers, empowering them with the tools they need to commercialize their discoveries,
disruptively innovate, and advance the prevention, diagnosis, and treatment of SUDs.
The Discovery to Commercialization Program for Substance Abuse Prevention and Treatment
(D2C: SAPT) curriculum will be systematically developed, implemented, and evaluated during this 5-year grant
period. The cornerstone of the proposed initiative is a new Certificate in Entrepreneurship at the Johns
Hopkins University Carey Business School (Aim 2). This program will leverage our experience in teaching
entrepreneurship to scientists at Johns Hopkins and be customized to SUD researchers. The asynchronous
online modules developed for the certificate program will be distributed widely (Aim 1), and through our
educational efforts we will intentionally build (Aim 3) and diversify (Aim 4) the community that can support
translation of discovery to market and impact SUDs.
This will be a specialized program for SUD researchers aimed at scientists at all career levels that is
grounded in theoretical frameworks and complemented by professional education related to entrepreneur
identity formation and community building. D2C: SAPT will comprise three parts: asynchronous modules
consisting of topics in ideation, market discovery, intellectual property, regulatory strategy, business, and
financial modeling, an in-person multi-day workshop comprising observations in SUD clinics, conversations
with stakeholders, design, and prototyping, and a mentored experiential learning component culminating in a
pitch competition. Program graduates will be equipped to apply for translational funding, patents, and to license
intellectual property or launch companies. More broadly, they will be part of a large virtual community of
researchers and practitioners and will play a role in transforming the culture of academic scientists. With a
keen understanding of the gaps that exist in the SUD field, the types of innovations that are possible, and the
process needed to train scientists in moving their discoveries to market, this training program will have
substantial public health impact by facilitating the launch of projects that move clinical practice in SUD to the
next generation of solutions.
项目摘要
药物使用障碍(SUD)的投资不足,并继续依靠
同样的方法不起作用。在此提案中,我们积极寻求支持颠覆性创新
阻止泡沫的上升潮流并刺激进步。这种干扰最有可能来自
积极参与治疗和促进对泡沫的知识。但是许多人都不知道
在发现商业化中的价值。我们的总体目标是让更多的基本科学家认为
像企业家一样,可以访问他们从事商业化所需的资源
过程。通过我们提出的任务,我们将开发和提供经过精心策划的企业家教育
对于基础科学研究人员,使他们能够使用他们所需的工具来商业化发现的工具,
破坏创新,并提高SUD的预防,诊断和治疗。
预防药物滥用和治疗的商业化计划
(D2C:SAPT)课程将在此5年赠款中系统地开发,实施和评估
时期。拟议倡议的基石是约翰斯的新企业家证书
霍普金斯大学凯里商学院(AIM 2)。该计划将利用我们在教学方面的经验
约翰·霍普金斯(Johns Hopkins)的科学家企业家精神,并向SUD研究人员定制。异步
为证书计划开发的在线模块将被广泛分发(AIM 1),并通过我们的
教育努力我们将有意建立(目标3)并多样化(目标4)可以支持的社区
将发现向市场和影响SUD的翻译。
这将是针对SUD研究人员的专业计划,针对所有职业水平的科学家
基于理论框架,并接受与企业家有关的专业教育
身份形成和社区建设。 D2C:SAPT将包括三个部分:异步模块
包括构想,市场发现,知识产权,监管策略,业务和
财务建模,一个面对面的多日研讨会,包括在SUD诊所进行观察,对话
利益相关者,设计和原型制作,以及指导的体验学习组成部分最终
球场比赛。课程毕业生将有能力申请翻译资金,专利和许可
知识产权或成立公司。更广泛地说,它们将成为大型虚拟社区的一部分
研究人员和从业人员将在改变学术科学家的文化中发挥作用。与
敏锐地了解SUD领域中存在的差距,可能的创新类型以及
需要培训科学家将其发现转移到市场所需的过程,该培训计划将具有
通过促进将SUD临床实践推动的项目推出的实质性公共卫生影响很大
下一代解决方案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kelly E Dunn其他文献
The IMPOWR Network Divided or Single Exposure Study (DOSE) Protocol: A Randomized Controlled Comparison of Once Versus Split Dosing of Methadone for the Treatment of Comorbid Chronic Pain and Opioid Use Disorder.
IMPOWR 网络分次或单次暴露研究 (DOSE) 方案:一次与分次给药美沙酮治疗共病慢性疼痛和阿片类药物使用障碍的随机对照比较。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Greer McKendrick;Will Davis;Michael Sklar;Nicole Brown;Emma Pattillo;Patrick H. Finan;Denis Antoine;Vickie Walters;Kelly E Dunn - 通讯作者:
Kelly E Dunn
The Public Health Challenge of Δ8-THC and Derived Psychoactive Cannabis Products.
Δ8-THC 和衍生的精神活性大麻产品的公共卫生挑战。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Jennifer M Whitehill;Kelly E Dunn;Renee M Johnson - 通讯作者:
Renee M Johnson
Kelly E Dunn的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kelly E Dunn', 18)}}的其他基金
Randomized Clinical Trial Intervention to Treat Chronic Pain Among Persons Maintained on Methadone for Opioid Use Disorder
随机临床试验干预治疗因阿片类药物使用障碍而维持美沙酮治疗的慢性疼痛
- 批准号:
10624868 - 财政年份:2022
- 资助金额:
$ 34.53万 - 项目类别:
Discovery to Commercialization Program for Substance Abuse Prevention and Treatment (D2C: SAPT)
药物滥用预防和治疗发现到商业化计划(D2C:SAPT)
- 批准号:
10665788 - 财政年份:2022
- 资助金额:
$ 34.53万 - 项目类别:
Randomized Clinical Trial Intervention to Treat Chronic Pain Among Persons Maintained on Methadone for Opioid Use Disorder
随机临床试验干预治疗因阿片类药物使用障碍而维持美沙酮治疗的慢性疼痛
- 批准号:
10458799 - 财政年份:2022
- 资助金额:
$ 34.53万 - 项目类别:
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
评估具有临床意义的阿片类药物戒断表型
- 批准号:
10580802 - 财政年份:2021
- 资助金额:
$ 34.53万 - 项目类别:
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
评估具有临床意义的阿片类药物戒断表型
- 批准号:
10401839 - 财政年份:2021
- 资助金额:
$ 34.53万 - 项目类别:
Evaluating Suvorexant for Sleep Disturbance in Opioid Use Disorder
评估 Suvorexant 对阿片类药物使用障碍患者睡眠障碍的影响
- 批准号:
9899225 - 财政年份:2019
- 资助金额:
$ 34.53万 - 项目类别:
Evaluating Suvorexant for Sleep Disturbance in Opioid Use Disorder
评估 Suvorexant 对阿片类药物使用障碍患者睡眠障碍的影响
- 批准号:
9790420 - 财政年份:2019
- 资助金额:
$ 34.53万 - 项目类别:
Evaluating Suvorexant for Sleep Disturbance in Opioid Use Disorder
评估 Suvorexant 对阿片类药物使用障碍患者睡眠障碍的影响
- 批准号:
10454583 - 财政年份:2019
- 资助金额:
$ 34.53万 - 项目类别:
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans
A118G SNP 和 OPRM1 基因阿片类药物介导的人类作用
- 批准号:
8925834 - 财政年份:2014
- 资助金额:
$ 34.53万 - 项目类别:
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans
A118G SNP 和 OPRM1 基因阿片类药物介导的人类作用
- 批准号:
8594898 - 财政年份:2014
- 资助金额:
$ 34.53万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The role of state agencies in mental health services for individuals with co-occurring intellectual and developmental disabilities and mental illness
国家机构在为同时患有智力和发育障碍以及精神疾病的个人提供心理健康服务方面的作用
- 批准号:
10534976 - 财政年份:2023
- 资助金额:
$ 34.53万 - 项目类别:
2023 Cellular and Molecular Mechanisms of Toxicity Gordon Research Conference and Seminar
2023细胞和分子毒性机制戈登研究会议暨研讨会
- 批准号:
10672627 - 财政年份:2023
- 资助金额:
$ 34.53万 - 项目类别:
Multilevel community-centered intervention to reduce pregnancy related and associated morbidity and mortality (PRAMM) disparities in Non-Hispanic Black and Hispanic Medicaid-insured individuals
以社区为中心的多层次干预措施,以减少非西班牙裔黑人和西班牙裔医疗补助保险个人中与妊娠相关和相关的发病率和死亡率 (PRAMM) 差异
- 批准号:
10755549 - 财政年份:2023
- 资助金额:
$ 34.53万 - 项目类别:
A digital health intervention to increase condom use among adolescent sexual minority males
数字健康干预措施可增加青少年性少数男性的安全套使用率
- 批准号:
10785368 - 财政年份:2023
- 资助金额:
$ 34.53万 - 项目类别:
Summer Program in Undergraduate Urology Research (SPUUR)
本科生泌尿学研究暑期课程(SPUUR)
- 批准号:
10557612 - 财政年份:2022
- 资助金额:
$ 34.53万 - 项目类别: